Delonix Bioworks Announces First Participant Dosed in Phase 1 Clinical Trial of Next-Generation MenB OMV Vaccine DX-104 in China
SHANGHAI, July 13, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, today announced that the first participant has been dosed in its Phase 1 clinical trial of DX-104

![Image: [Official Launch] AGONG Durian Uses Blockchain to Authenticate Every Musang King](http://prnewswire.vietreader.com/thumb/208x280/2026-07/official-launch-agong-durian-uses-blockchain-to-authenticate-every-musang-king-1.jpg)






